TACTI-002 has also been updated on clinicaltrials.gov. It looks we'll have to wait until mid-2023 until the trial is completed. Although given that four out of the 74 additional patients were already recruited into the NSCLC expansion trial, hopefully this will be sped up (at any rate as everyone knows here, VLA was still only halfway through its two phase1b Keytruda combination trials before it was bought out by MSD)
https://clinicaltrials.gov/ct2/history/NCT03625323?A=9&B=10&C=Side-by-Side#StudyPageTop
https://clinicaltrials.gov/ct2/show...T02652130&draw=2&rank=8&load=cart
Ann: Immutep expands TACTI-002 Collaboration Trial with MSD, page-2
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 133736 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |